| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 02/28/2001 | EP1078105A1 Replication defective hiv vaccine |
| 02/28/2001 | EP1078093A1 Vaccines, immunotherapeutics and methods for using the same |
| 02/28/2001 | EP1078092A2 Expression vectors for stimulating an immune response and methods of using the same |
| 02/28/2001 | EP1078077A1 Nucleic acids and proteins from pineapple stem |
| 02/28/2001 | EP1078073A1 Chitinase chitin-binding fragments |
| 02/28/2001 | EP1078066A2 Basb028 polypeptides and polynucleotides encoding therefor from moraxella catarrhalis |
| 02/28/2001 | EP1078065A2 Compounds from moraxella catarrhalis |
| 02/28/2001 | EP1078064A2 Compounds from moraxella catarrhalis |
| 02/28/2001 | EP1078063A2 Basb029polynucleotide(s) and polypeptides from neisseria meningitis |
| 02/28/2001 | EP1078062A2 Growth-associated protease inhibitor heavy chain precursor |
| 02/28/2001 | EP1078060A2 Antibodies to dendritic cells and human dendritic cell populations and uses thereof |
| 02/28/2001 | EP1078055A2 Dimers of the hla-b27 heavy chain extracellular domain and uses thereof |
| 02/28/2001 | EP1078053A2 METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES |
| 02/28/2001 | EP1078046A1 97 human secreted proteins |
| 02/28/2001 | EP1078043A1 New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines |
| 02/28/2001 | EP1078018A2 Process for extracting carotenes from carotene-containing materials |
| 02/28/2001 | EP1078007A2 Verotoxin b subunit for immunization |
| 02/28/2001 | EP1078006A1 Diagnosis and treatment of hepatic disorders |
| 02/28/2001 | EP1078005A1 Methods for amyloid removal using anti-amyloid antibodies |
| 02/28/2001 | EP1078003A1 PLASMIN INHIBITORS FROM THE AUSTRALIAN BROWN SNAKE $i(PSEUDONAJA TEXTILIS TEXTILIS) |
| 02/28/2001 | EP1078000A2 Peptides |
| 02/28/2001 | EP1077999A2 Moraxella catharralis proteins |
| 02/28/2001 | EP1077989A1 Tumor associated antigen encoded by the reverse strand of a new ubiquitously expressed gene |
| 02/28/2001 | EP1077983A2 Pria |
| 02/28/2001 | EP1077724A2 Methods and products related to metabolic interactions in disease |
| 02/28/2001 | EP1077723A1 Methods and use of compositions comprising tnf-rii(p75) agonists for treating asthma and other allergic conditions |
| 02/28/2001 | EP1077722A2 Methods and products for inducing mucosal immunity |
| 02/28/2001 | EP1077721A1 Prevention and treatment of hypergastrinemia |
| 02/28/2001 | EP1077720A2 Composition for inducing a tumor-specific immune response, method for the production and utilization of said composition in the treatment of neoplasia |
| 02/28/2001 | EP1077719A1 Vaccine delivery system |
| 02/28/2001 | EP1077716A1 Method for the treatment of gastroesophageal reflux disease |
| 02/28/2001 | EP1077711A2 Treatment of papilloma virus infection using a mycobacterium |
| 02/28/2001 | EP1077708A1 Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
| 02/28/2001 | EP0695192B1 Gonococcal anti-idiotypic antibodies and methods and compositions using them |
| 02/28/2001 | EP0686030B1 Microparticles loaded with antigen and pharmaceutical compositions containing these microparticles. |
| 02/28/2001 | EP0672142B1 Multivalent and multispecific binding proteins, their manufacture and use |
| 02/28/2001 | EP0584284B1 Recombinant dna-derived cholera toxin subunit analogs |
| 02/28/2001 | CN1285754A Monoclonal human matural antibodies |
| 02/28/2001 | CN1285753A Transdermal delivery of particulate vaccine compositions |
| 02/28/2001 | CN1285752A Processes of making north american ginseng fractions, products containing them, and use as immunomodulators |
| 02/28/2001 | CN1285744A Use of histamine for elevating blood histamine levels |
| 02/28/2001 | CN1285514A Medicine box bof testing anti-hepatitis C virus antibody |
| 02/28/2001 | CN1285217A Method for extracting sticky biological stock solution and use thereof |
| 02/28/2001 | CN1062662C Process for preparing human immunodeficiency virus and hapatitis C virus antibody united diagnostic reagent |
| 02/28/2001 | CN1062605C Process for preparation of Escherichia coli vaccine |
| 02/28/2001 | CN1062601C Viral vaccines |
| 02/28/2001 | CN1062449C Method for preparation of fodder used in cultivating crustacea |
| 02/27/2001 | US6194561 Oligonucleotide probes of defined nucleotide sequences which are complementary to second exon of class ii hla beta chain gene; diagnosis of susceptibility to insulin-dependent diabetes mellitus and pemphigus vulgaris; antidiabetic agents |
| 02/27/2001 | US6194560 Synthetic escherichia coli gene which encodes lt-b; the dna sequence is optimized for plant codon usage; feeds; foods |
| 02/27/2001 | US6194549 Partially purified preparation of pen5, a glycoprotein pair; for detecting and/or removing natural killer cells from a mixed population of cells |
| 02/27/2001 | US6194546 Influenza virus haemagglutinin which has a heterologous epitope at antigenic site a; vaccines against foot-and-mouth disease, poliovirus, human rhinovirus, hepatitis b virus, plasmodium and bacteria |
| 02/27/2001 | US6194544 Cyclic semi-random peptide libraries |
| 02/27/2001 | US6194542 Method of detecting cytomegalovirus (CMV) |
| 02/27/2001 | US6194388 Immunomodulatory oligonucleotides |
| 02/27/2001 | US6194210 Hepatitis A virus culture process |
| 02/27/2001 | US6194187 Apoptosis-inducing protein and gene encoding the same |
| 02/27/2001 | US6194186 Human protein kinase and kinase inhibitors |
| 02/27/2001 | US6194162 Method of screening for compounds that bind P2x receptor |
| 02/27/2001 | US6194161 Staphylococcus aureus antigen |
| 02/27/2001 | US6194142 Nucleotide sequences derived from the genome of retroviruses of the HIV-1, HIV-2, and SIV type, and their uses in particular for the amplification of the genomes of these retroviruses and for the in vitro diagnosis of the diseases due to these viruses |
| 02/27/2001 | US6194136 Cryoprotective solutions comprising DMSO, PG, 2,3-butanediol,raffinose and PVP |
| 02/27/2001 | US6193984 Pharmaceutical composition of herpes simplex virus typ-1 (HSV-1) glycoproteins |
| 02/27/2001 | US6193983 Equine herpesvirus glycoproteins |
| 02/27/2001 | US6193982 Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120 |
| 02/27/2001 | US6193981 Methods and compositions for impairing multiplication of HIV-1 |
| 02/27/2001 | US6193970 Potentiating local inflammatory or immune response to administration of tumor antigen in mammalian subject by administering tumor antigen in form of tumor cells, or subcellular antigenic material and cytokine or cytokines |
| 02/27/2001 | US6193969 Preventing, ameliorating, or treating septic shock or its symptoms by administering igg (immunoglobulin g) fab fragments reactive towards tnf.alpha.(tumor nercosis factor), wherein igg fab fragments are derived from polyclonal igg |
| 02/27/2001 | US6193966 Administering bispecific protein or peptide molecule, comprising a first binding determinate which binds to fc.alpha.receptor without being blocked by immunoglobulin a and second binding determinant which binds to target antigen |
| 02/27/2001 | US6193965 Administering therapeutically effective amount of reagent which modulates kinase activity for treating cell proliferative disorder associated with c-jun n-terminal kinase disorder, |
| 02/27/2001 | US6193963 Method of treating tumor-bearing patients with human plasma hyaluronidase |
| 02/27/2001 | CA2123222C Gram-negative bacterial vaccines |
| 02/27/2001 | CA2110582C Modified sialyl lewis a compounds |
| 02/27/2001 | CA2066031C Methods for reducing non-target retention of immunoconjugates and metabolites thereof |
| 02/27/2001 | CA2025598C Chimaeric hepadnavirus core antigen proteins |
| 02/27/2001 | CA1341191C Detection of neu gene expression and products |
| 02/22/2001 | WO2001013117A2 Proteins, genes and their use for diagnosis and treatment of breast cancer |
| 02/22/2001 | WO2001012818A1 Neutral cerebral-sphingomyelinase |
| 02/22/2001 | WO2001012816A2 Porcine endovirus gag and env and diagnostic uses thereof |
| 02/22/2001 | WO2001012812A2 Baff receptor (bcma), an immunoregulatory agent |
| 02/22/2001 | WO2001012811A1 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 02/22/2001 | WO2001012797A2 Method of separating rotavirus variants and live attenuated rotavirus vaccine |
| 02/22/2001 | WO2001012790A2 Isomerase proteins |
| 02/22/2001 | WO2001012781A1 13 human colon and colon cancer associated proteins |
| 02/22/2001 | WO2001012775A2 25 human secreted proteins |
| 02/22/2001 | WO2001012674A1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 02/22/2001 | WO2001012673A1 Pgpcr-3 polypeptides and dna sequences thereof |
| 02/22/2001 | WO2001012672A2 Cytokine receptor common gamma chain like |
| 02/22/2001 | WO2001012670A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | WO2001012664A2 Notch receptor ligands and uses thereof |
| 02/22/2001 | WO2001012661A2 RECEPTOR-MEDIATED UPTAKE OF AN EXTRACELLULAR BCL-xL FUSION PROTEIN INHIBITS APOPTOSIS |
| 02/22/2001 | WO2001012649A1 Aga |
| 02/22/2001 | WO2001012598A2 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 02/22/2001 | WO2001012223A2 Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein |
| 02/22/2001 | WO2001012222A1 Immunological tolerance-induction agent |
| 02/22/2001 | WO2001012221A1 Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them |
| 02/22/2001 | WO2001012220A1 Non-immunosuppressant hiv tat |
| 02/22/2001 | WO2001012219A1 Pneumococcal vaccines |
| 02/22/2001 | WO2001012218A1 Methods and materials for the treatment of prostatic carcinoma |
| 02/22/2001 | WO2001012217A1 Therapeutic antibody against muc-1 antigen and methods for their use |
| 02/22/2001 | WO2001012216A1 Heat shock fusion-based vaccine system |